EMAIL THIS PAGE TO A FRIEND

Cancer research

Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment.


PMID 25125656

Abstract

Eradicating malignant tumors by vaccine-elicited host immunity remains a major medical challenge. To date, correlates of immune protection remain unknown for malignant mesothelioma. In this study, we demonstrated that antigen-specific CD8(+) T-cell immune response correlates with the elimination of malignant mesothelioma by a model PD-1-based DNA vaccine. Unlike the nonprotective tumor antigen WT1-based DNA vaccines, the model vaccine showed complete and long-lasting protection against lethal mesothelioma challenge in immunocompetent BALB/c mice. Furthermore, it remained highly immunogenic in tumor-bearing animals and led to therapeutic cure of preexisting mesothelioma. T-cell depletion and adoptive transfer experiments revealed that vaccine-elicited CD8(+) T cells conferred to the protective efficacy in a dose-dependent way. Also, these CD8(+) T cells functioned by releasing inflammatory IFNγ and TNFα in the vicinity of target cells as well as by initiating TRAIL-directed tumor cell apoptosis. Importantly, repeated DNA vaccinations, a major advantage over live-vectored vaccines with issues of preexisting immunity, achieve an active functional state, not only preventing the rise of exhausted PD-1(+) and Tim-3(+) CD8(+) T cells but also suppressing tumor-induced myeloid-derived suppressive cells and Treg cells, with the frequency of antigen-specific CD8(+) T cells inversely correlating with tumor mass. Our results provide new insights into quantitative and qualitative requirements of vaccine-elicited functional CD8(+) T cells in cancer prevention and immunotherapy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA004472
Anti-CD4 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1405577
Anti-CD8A antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA037756
Anti-CD8A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4700059
Monoclonal Anti-CD4 , (N-terminal) antibody produced in mouse, clone MEM-241, purified immunoglobulin, buffered aqueous solution
SAB4700054 Monoclonal Anti-CD4 antibody produced in mouse, clone MEM-16, purified immunoglobulin, buffered aqueous solution
SAB4700065
Monoclonal Anti-CD4 antibody produced in mouse, clone MEM-115, purified immunoglobulin, buffered aqueous solution
SAB4700733 Monoclonal Anti-CD4 antibody produced in mouse, clone OX-35, purified immunoglobulin, buffered aqueous solution
SAB4100489
Monoclonal Anti-CD4 antibody produced in mouse, clone CD4 -A409, culture supernatant
AMAB90754
Monoclonal Anti-CD4 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0395, purified immunoglobulin, buffered aqueous glycerol solution
C7423
Monoclonal Anti-CD8 antibody produced in mouse, clone UCHT-4, purified immunoglobulin, buffered aqueous solution
SAB4700084 Monoclonal Anti-CD8 antibody produced in mouse, clone MEM-31, purified immunoglobulin, buffered aqueous solution
SAB4700089 Monoclonal Anti-CD8 antibody produced in mouse, clone MEM-87, purified immunoglobulin, buffered aqueous solution
SAB1402142
Monoclonal Anti-CD8A antibody produced in mouse, clone 4B9, purified immunoglobulin, buffered aqueous solution